Gram Research analysis of a 2026 pilot case series found that five women with lipedema lost between 7.7 and 17.1 kg over about six months of diet, exercise, and tirzepatide treatment. The study cannot prove the drug caused the loss, because all participants also changed their diet and exercise.
According to research reviewed by Gram, a small 2026 pilot study followed five women with lipedema, a condition that causes painful fat buildup mainly in the legs, and excess body weight. All five first spent 8 to 9 weeks on a low-carbohydrate Mediterranean diet with regular exercise. Four then added tirzepatide, a weekly injection that helps people lose weight, for the next 14 to 16 weeks, while one chose not to use medication. Across the group, weight loss ranged from 7.7 to 17.1 kg. Body fat dropped in four of the five women, and blood sugar and insulin resistance measures improved in most. Pain scores generally improved among those on tirzepatide. The researchers were clear that these results cannot be credited to the drug alone, because everyone also changed their diet and exercise. Larger studies are needed before firm conclusions can be drawn.
Key Statistics
A 2026 pilot case series of five women with lipedema and excess body weight found that weight loss ranged from 7.7 to 17.1 kg over 22 to 25 weeks of combined diet, exercise, and tirzepatide treatment.
In that 2026 study of five women, body fat percentage decreased in four participants, while fasting glucose and insulin resistance measures fell in most cases.
The 2026 study, published in the Journal of Clinical Medicine, reported no serious adverse events among the four women who received tirzepatide, though the study was not designed to measure safety.
The Quick Take
- What they studied: Researchers wanted to know what happened to body weight, body fat, pain, and blood markers in women with lipedema who used a combined program of diet, exercise, and the weight-loss medication tirzepatide.
- Who participated: Five women with lipedema and excess body weight were treated at a single clinic in 2025 and followed into 2026. Four used tirzepatide, and one declined medication. All five completed the program, so the total group was very small.
- Key finding: Weight loss among the five women ranged from 7.7 to 17.1 kg (about 17 to 38 pounds). Body fat percentage fell in four of the five women. Blood sugar and insulin resistance measures improved in most of the women, but cholesterol and other blood fat results were mixed.
- What it means for you: This study cannot tell you whether tirzepatide itself caused the changes, since everyone also changed their diet and exercise. It does suggest that a structured program with medical supervision may be worth discussing with a doctor if you have lipedema and struggle to lose weight.
The Research Details
This was a pilot case series, which means the researchers carefully described what happened to each person instead of comparing one group against another. Their approach was called ambispective, a term that combines looking back at records from 2025 with following people forward in 2026. Each woman’s measurements were recorded at set points: the start, the end of the diet and exercise phase, and the end of the medication phase.
In the first 8 to 9 weeks, every participant followed a low-carbohydrate Mediterranean diet and was advised to do aerobic and resistance exercise. No one took tirzepatide during this stage. After that, four women began a weekly tirzepatide injection, with doses between 2.5 and 7.5 mg, and continued for another 14 to 16 weeks. The fifth woman chose not to take the medication but kept up the diet and exercise plan.
The team measured body weight, body composition, muscle and fat thickness using ultrasound, blood tests, pain, and quality of life. The results were summarized for each woman separately rather than averaged together. The ethics committee approved the study, and each participant signed written consent for her data and photos to be published.
A case series is a useful first step when a condition is poorly studied. It lets researchers notice patterns, describe real-world treatment, and decide which questions deserve larger, more rigorous trials. Because lipedema has little research on weight-loss treatments, this kind of early observation helps guide future work.
The design has a clear limitation, though. With no control group, there is no way to know what would have happened to these women without the medication. Changes could come from the diet, the exercise, the passage of time, or other factors. That is why the authors describe their findings as hypothesis-generating, meaning they suggest ideas to test rather than proving them.
The study was reviewed and approved by a bioethics committee, and participants gave consent for their data to be published. It was conducted at one medical center, so the results may not apply to women in other settings. The paper was published in the Journal of Clinical Medicine, a peer-reviewed journal.
Readers should keep in mind that five people is an extremely small number. Results from so few people can swing widely due to chance, and one unusual case can change the overall picture. The study was also not designed to measure safety, so the reported lack of side effects should be treated as an observation, not proof that the treatment is safe for everyone.
What the Results Show
The most visible result was weight loss. Across the five women who finished the program, weight dropped by between 7.7 and 17.1 kg. Because the women started at different body sizes and followed different timelines, the researchers reported each person’s change individually rather than focusing on a single average.
Body composition told a similar story. Body fat percentage decreased in four of the five women. The lower-leg measurements and the thickness of fat under the skin generally went down as well, although the amount and location of change varied from person to person. This variation is consistent with lipedema, where fat tends to accumulate unevenly.
Muscle mass is an important part of the picture. Skeletal muscle mass decreased slightly in all four women who took tirzepatide. Some muscle loss is common during rapid weight loss, which is why the researchers recommended resistance exercise alongside diet changes. The study did not separate muscle loss caused by the medication from loss caused by the calorie reduction.
Blood sugar and insulin resistance improved in most of the women. Fasting glucose and a measure of insulin resistance called HOMA-IR both decreased in most cases. These improvements matter because insulin resistance is linked to type 2 diabetes and heart disease. Cholesterol and other blood fat results were mixed, with some going up and others going down, so no clear pattern emerged.
Pain and quality of life also changed. Scores on a standard health survey called SF-36 generally improved among the four women on tirzepatide, with bodily pain showing the clearest gains. However, the survey was only completed at two points in time, so changes during the diet phase could not be measured. Responses to a pressure pain test were inconsistent across the group, meaning the physical pain measure did not show a single clear trend.
The researchers reported no side effects, stomach problems, dose reductions, treatment pauses, or dropouts among the four women on tirzepatide. Because the study was not built to track safety, this should be read as a description of what happened to these five women, not as evidence that the treatment is safe in general.
Tirzepatide has been studied extensively in people with obesity and type 2 diabetes, where large trials have shown substantial weight loss. Those trials typically involve hundreds or thousands of people and compare the drug against placebo, which makes their findings much stronger than this small study. This pilot adds early information about a group that has been studied far less, women with lipedema.
Lipedema itself has been understudied, and most weight-loss research has not focused on it. The results here are consistent with what doctors already know about lifestyle changes and weight-loss medications, but they do not establish that tirzepatide works differently in lipedema. Researchers will need controlled trials to answer that question.
The most important limitation is that everyone received the same diet, exercise, and supplements. Because of this, the authors state that the changes cannot be attributed to tirzepatide or described as a lipedema-specific effect. The woman who declined medication was not a control group, so she cannot serve as a direct comparison.
The group was tiny, with only five completers, and the study was done at a single center. Results from so few people can be strongly affected by individual differences, and they may not apply to women with different body types, ages, or medical histories. Some measurements were only taken at certain points, so the full picture is incomplete.
Finally, the study was not designed to evaluate safety, and it did not follow the women long enough to know whether the weight loss would last. These are important gaps that larger, controlled studies would need to address.
The Bottom Line
Research shows that the combined program was followed by weight loss in all five women, with body fat decreasing in four. However, confidence in the tirzepatide-specific effect is low, because the study had no control group and included only five participants. Diet and exercise changes are widely supported for weight management, so those parts carry more confidence than the medication results. Anyone considering tirzepatide should discuss it with a qualified doctor who can weigh its benefits and risks for their situation.
Women with lipedema who have struggled to lose weight through diet and exercise alone may find this research relevant to discuss with their doctor. People with obesity or type 2 diabetes may also be interested, since insulin resistance improved in most participants. People who do not have lipedema, who are pregnant or planning pregnancy, or who have a history of certain thyroid cancers or pancreatitis should not assume these findings apply to them without medical advice. Tirzepatide is a prescription medication and is not appropriate for everyone.
In this study, weight loss occurred over roughly 22 to 25 weeks, with the diet and exercise phase lasting 8 to 9 weeks and the medication phase lasting 14 to 16 weeks. Most people can expect gradual changes rather than rapid results, and the amount of change differed widely between the women. Results from a pilot study like this cannot predict what any individual will experience, and benefits such as pain relief or better blood sugar may take longer to appear or may not appear at all.
Frequently Asked Questions
How much weight did women with lipedema lose on tirzepatide in the 2026 study?
In a 2026 pilot case series of five women, weight loss ranged from 7.7 to 17.1 kg over about six months. All participants also followed a low-carbohydrate Mediterranean diet and exercise plan, so the results cannot be attributed to the medication alone.
Can tirzepatide cure lipedema?
The 2026 pilot study did not find that tirzepatide cures lipedema. Researchers observed weight and body fat changes in some women, but the study had no control group and only five participants. Lipedema is a chronic condition, and larger controlled trials are needed before any claims about treatment effects can be made.
Is a Mediterranean diet good for lipedema weight loss?
In a 2026 pilot study, women with lipedema followed a low-carbohydrate Mediterranean diet for 8 to 9 weeks alongside exercise. Most showed some changes in weight, body fat, or blood sugar. The study could not separate the diet’s effect from the medication’s effect, so its specific contribution remains unclear.
Are there side effects of tirzepatide in women with lipedema?
The 2026 pilot study reported no adverse events, stomach symptoms, or treatment discontinuations among the four women who took tirzepatide. However, the study was not designed to assess safety, and five participants is too few to rule out side effects. Talk with a doctor about risks before starting any prescription medication.
Want to Apply This Research?
- Record your body weight once a week, at the same time of day, using the same scale. Add a monthly measurement of waist and thigh circumference, since these changes can show progress even when weight changes slowly. If you have lipedema, note any pain on a 0 to 10 scale each week.
- Build a weekly routine that combines a low-carbohydrate, Mediterranean-style eating pattern with at least two sessions of resistance training and regular aerobic activity such as brisk walking. Use the app to log meals and workouts so you can see patterns over time. If you are considering a prescription medication, use the app to write down questions for your doctor.
- Track weight, measurements, and pain or mobility notes over at least six months, rather than judging progress by a single week. Share the trends with your healthcare provider at regular visits, especially if you are taking a medication. Watch for changes in how you feel, such as stomach discomfort or unusual fatigue, and report them promptly. Review your data every three months to decide whether your plan is working.
This article summarizes a very small pilot study of five women and is for general information only. It does not establish that tirzepatide or any diet or exercise plan treats lipedema or is safe for you. Tirzepatide is a prescription medication with possible serious side effects. Consult a qualified healthcare provider before making any changes to your medication, diet, or exercise routine, especially if you are pregnant, have diabetes, or have a history of thyroid or pancreatic conditions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.